Wall Street analysts expect Marrone Bio Innovations Inc (NASDAQ:MBII) to post earnings per share of ($0.04) for the current quarter, according to Zacks. Two analysts have issued estimates for Marrone Bio Innovations’ earnings, with estimates ranging from ($0.05) to ($0.03). Marrone Bio Innovations reported earnings per share of ($0.05) during the same quarter last year, which would indicate a positive year over year growth rate of 20%. The business is scheduled to issue its next earnings report on Thursday, March 12th.

According to Zacks, analysts expect that Marrone Bio Innovations will report full year earnings of ($0.29) per share for the current year. For the next fiscal year, analysts expect that the company will post earnings of ($0.15) per share, with EPS estimates ranging from ($0.20) to ($0.07). Zacks’ EPS calculations are a mean average based on a survey of sell-side analysts that follow Marrone Bio Innovations.

MBII has been the topic of several research reports. National Securities restated a “buy” rating and set a $2.50 price objective on shares of Marrone Bio Innovations in a research note on Friday, August 9th. HC Wainwright restated a “buy” rating and set a $2.50 price objective on shares of Marrone Bio Innovations in a research note on Monday, August 12th.

A number of hedge funds and other institutional investors have recently made changes to their positions in MBII. BlackRock Inc. raised its stake in Marrone Bio Innovations by 0.8% during the second quarter. BlackRock Inc. now owns 2,657,546 shares of the basic materials company’s stock valued at $3,986,000 after buying an additional 22,254 shares in the last quarter. A.R.T. Advisors LLC bought a new position in Marrone Bio Innovations during the second quarter valued at about $28,000. River & Mercantile Asset Management LLP bought a new position in Marrone Bio Innovations during the second quarter valued at about $843,000. Susquehanna International Group LLP bought a new position in Marrone Bio Innovations during the second quarter valued at about $30,000. Finally, Fairpointe Capital LLC raised its holdings in Marrone Bio Innovations by 42.7% during the third quarter. Fairpointe Capital LLC now owns 415,400 shares of the basic materials company’s stock valued at $586,000 after buying an additional 124,400 shares in the last quarter. Hedge funds and other institutional investors own 44.18% of the company’s stock.

NASDAQ MBII traded down $0.03 on Monday, hitting $1.05. 42,862 shares of the stock traded hands, compared to its average volume of 120,616. The stock has a 50-day moving average of $1.26 and a 200 day moving average of $1.41. Marrone Bio Innovations has a twelve month low of $1.02 and a twelve month high of $1.92. The company has a market capitalization of $140.07 million, a P/E ratio of -5.00 and a beta of -0.22. The company has a current ratio of 1.05, a quick ratio of 0.69 and a debt-to-equity ratio of 0.94.

About Marrone Bio Innovations

Marrone Bio Innovations, Inc provides bio-based pest management and plant health products primarily for agricultural and water markets in the United States and internationally. It offers herbicides; fungicides; nematicides; insecticides; algaecides for algae control; molluscicides for mussel and snail control; plant growth and stress regulators; and water treatment products for various applications, such as hydroelectric and thermoelectric power generation, industrial applications, drinking water, aquaculture, irrigation, and recreation.

Recommended Story: Backdoor Roth IRA

Get a free copy of the Zacks research report on Marrone Bio Innovations (MBII)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Marrone Bio Innovations (NASDAQ:MBII)

Receive News & Ratings for Marrone Bio Innovations Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marrone Bio Innovations and related companies with MarketBeat.com's FREE daily email newsletter.